Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Salix Pharmaceuticals Ltd announces acceptance of NDA filing for budesonide foam in patients with distal ulcerative colitis


Thursday, 30 Jan 2014 07:00am EST 

Salix Pharmaceuticals Ltd:Says the Food and Drug Administration (FDA) has accepted for filing a New Drug Application for Budesonide 2 mg Rectal Foam for the induction of remission in patients with active mild to moderate distal ulcerative colitis. 

Company Quote

158.3
1.12 +0.71%
21 Aug 2014